Literature DB >> 3718096

Renal disease in patients with massive obesity.

B L Kasiske, J T Crosson.   

Abstract

During a four-year period, 17 massively obese patients without clinically apparent systemic disease underwent renal biopsy for marked proteinuria. Clinical information and biopsy results were compared with those in 34 normal-body-weight controls matched for age, sex, and similar presentation. Histopathologic changes characteristic of focal glomerulosclerosis were found in nine (53%) of the obese patients and two (6%) of the controls. In addition, five (29%) of the obese patients had occult diabetic nephropathy, while no diabetic changes were seen in controls. Clinically, obese patients resembled controls in most respects. Serum albumin level, however, was higher than in controls (3.5 +/- 0.2 vs 2.5 +/- 0.1 g/dL). Indeed, obese patients with focal glomerulosclerosis had normal serum albumin levels (4.0 +/- 0.1 g/dL). Thus, primary renal disease in massively obese patients with marked proteinuria differed in several important respects from that seen in normal-body-weight patients with a similar degree of proteinuria.

Entities:  

Mesh:

Year:  1986        PMID: 3718096

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  14 in total

1.  Beneficial effects of statins on the kidney.

Authors:  B Afzali; D J A Goldsmith
Journal:  J Clin Pathol       Date:  2004-07       Impact factor: 3.411

Review 2.  Impact of obesity on drug metabolism and elimination in adults and children.

Authors:  Margreke J E Brill; Jeroen Diepstraten; Anne van Rongen; Simone van Kralingen; John N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

Review 3.  Hyperfiltration nephropathy as a cause of late graft loss in renal transplantation.

Authors:  C Modlin; D Goldfarb; A C Novick
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

4.  Roux-en-Y gastric bypass reverses renal glomerular but not tubular abnormalities in excessively obese diabetics.

Authors:  Jabbar Saliba; Nader R Kasim; Robyn A Tamboli; James M Isbell; Pam Marks; Irene D Feurer; Alp Ikizler; Naji N Abumrad
Journal:  Surgery       Date:  2009-12-11       Impact factor: 3.982

5.  Impact of obesity on renal structure and function in the presence and absence of hypertension: evidence from melanocortin-4 receptor-deficient mice.

Authors:  Jussara M do Carmo; Lakshmi S Tallam; John V Roberts; Elizabeth L Brandon; John Biglane; Alexandre A da Silva; John E Hall
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-07-15       Impact factor: 3.619

6.  Medaka fish, Oryzias latipes, as a model for human obesity-related glomerulopathy.

Authors:  Koichiro Ichimura; Yusuke Kawashima; Tomomi Nakamura; Rebecca Powell; Yuya Hidoh; Shuji Terai; Isao Sakaida; Yoshio Kodera; Takashi Tsuji; Jian-Xing Ma; Tatsuo Sakai; Hiroyuki Matsumoto; Tomoko Obara
Journal:  Biochem Biophys Res Commun       Date:  2013-01-23       Impact factor: 3.575

7.  Changes in body weight predict CKD in healthy men.

Authors:  Seungho Ryu; Yoosoo Chang; Hee-Yeon Woo; Soo-Geun Kim; Dong-Il Kim; Won Sool Kim; Byung-Seong Suh; Nam-Kyong Choi; Jong-Tae Lee
Journal:  J Am Soc Nephrol       Date:  2008-05-21       Impact factor: 10.121

8.  Clinical features and long-term renal outcomes of Japanese patients with obesity-related glomerulopathy.

Authors:  Nobuo Tsuboi; Kentaro Koike; Keita Hirano; Yasunori Utsunomiya; Tetsuya Kawamura; Tatsuo Hosoya
Journal:  Clin Exp Nephrol       Date:  2012-11-08       Impact factor: 2.801

9.  Chronic kidney disease, obesity, and hypertension: the role of leptin and adiponectin.

Authors:  M Tesauro; A Mascali; O Franzese; S Cipriani; C Cardillo; N Di Daniele
Journal:  Int J Hypertens       Date:  2012-12-23       Impact factor: 2.420

10.  Proximal tubular hypertrophy and enlarged glomerular and proximal tubular urinary space in obese subjects with proteinuria.

Authors:  Ana Tobar; Yaacov Ori; Sydney Benchetrit; Gai Milo; Michal Herman-Edelstein; Boris Zingerman; Netta Lev; Uzi Gafter; Avry Chagnac
Journal:  PLoS One       Date:  2013-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.